Das Kshaunish, Ghoshal Uday C, Dhali Gopal K, Benjamin Jaya, Ahuja Vineet, Makharia Govind K
Division of Gastroenterology, School of Digestive and Liver Diseases, Institute of Post-Graduate Medical Education & Research, Kolkata, India.
Dig Dis Sci. 2009 May;54(5):1099-107. doi: 10.1007/s10620-008-0469-6. Epub 2008 Sep 4.
Although Crohn's disease is thought to be rare and intestinal tuberculosis common in India, Crohn's disease is being reported more often. However, there is a lack of systematic study on Crohn's disease from India. In this analysis of data from three inflammatory bowel disease clinics (two in northern India and one in eastern India), criteria for Crohn's disease were applied retrospectively: (1) World Health Organization (WHO) criteria; or (2) compatible histology (European Crohn's and Colitis Organization) or failure of response to 4-8 weeks of anti-tuberculosis therapy (Asia-Pacific guidelines); or (3) compatible macroscopic, radiologic, colonoscopic features (European Crohn's and Colitis Organization). Others were classified as probable Crohn's disease. The Montreal classification was used for disease phenotype. Age at onset and duration of symptoms (182 patients, 117 male) were 34.5 (+/-13.6; 7-73) years and 3.0 (+/-5.8; 0.1-36) years, respectively. Diarrhea (68%), abdominal pain (62%), and weight loss (57%) were common. The common intestinal complications were occult (27%) and overt (40%) gastrointestinal bleeding and obstruction (28%). There were 141 (78%) and 41 (22%) with definite and probable Crohn's disease respectively. Of 147 (81%) available histopathology specimens (endoscopic biopsy in 110; 75%), 31 (21%) had granuloma. Seventy-one out of 166 (43%) had received anti-tuberculosis therapy in the past. Results from the Montreal classification were as follows: age at onset, A1:A2:A3 6%:64%:30%; location of disease, L1:L2:L3:L4 32%:41%:23%:4%, and disease behavior, B1:B2:B3 51%:24%:25%. Twenty-six (15%) and 31 (17%) patients had upper gastrointestinal and perianal modifiers. The drugs used were: aminosalicylates (128, 70%), steroids (76, 42%), azathioprine (53, 29%), methotrexate (4, 2%), and salazopyrine (14, 8%). Sixty-six (36%) patients underwent surgical treatment. We concluded that the phenotype of Crohn's disease in India is very similar to that described in other regions of Asia and the West, except for a delay in diagnosis and a more complicated disease at diagnosis.
尽管在印度克罗恩病被认为罕见而肠结核常见,但现在克罗恩病的报告越来越多。然而,印度缺乏对克罗恩病的系统性研究。在对三家炎症性肠病诊所(两家位于印度北部,一家位于印度东部)的数据进行的此次分析中,回顾性地应用了克罗恩病的诊断标准:(1)世界卫生组织(WHO)标准;或(2)符合组织学标准(欧洲克罗恩病和结肠炎组织)或抗结核治疗4 - 8周无反应(亚太地区指南);或(3)符合宏观、放射学、结肠镜特征(欧洲克罗恩病和结肠炎组织)。其他则归类为可能的克罗恩病。采用蒙特利尔分类法对疾病表型进行分类。发病年龄和症状持续时间(182例患者,117例男性)分别为34.5(±13.6;7 - 73)岁和3.0(±5.8;0.1 - 36)年。腹泻(68%)、腹痛(62%)和体重减轻(57%)很常见。常见的肠道并发症为隐匿性(27%)和显性(40%)胃肠道出血以及肠梗阻(28%)。分别有141例(78%)和41例(22%)确诊为克罗恩病和可能的克罗恩病。在147份(81%)可获得的组织病理学标本中(110份为内镜活检;75%),31份(21%)有肉芽肿。166例中有71例(43%)过去接受过抗结核治疗。蒙特利尔分类法的结果如下:发病年龄,A1:A2:A3为6%:64%:30%;疾病部位,L1:L2:L3:L4为32%:41%:23%:4%,疾病行为,B1:B2:B3为51%:24%:25%。26例(15%)和31例(17%)患者有上消化道和肛周改变。使用的药物有:氨基水杨酸制剂(128例,70%);类固醇(76例,42%);硫唑嘌呤(53例,29%);甲氨蝶呤(4例,2%);柳氮磺胺吡啶(14例,8%)。66例(36%)患者接受了手术治疗。我们得出结论,印度克罗恩病的表型与亚洲其他地区和西方所描述的非常相似,只是诊断延迟且诊断时疾病更为复杂。